Corrigendum to “The humoral and cellular immune responses following booster vaccination with SARS-CoV-2 mRNA in people living with human immunodeficiency virus” [J. Infect. Chemother. 30 (2024) 417–422, (S1341321X23002866), (10.1016/j.jiac.2023.11.014)]

Yuji Matsumoto; Masayuki Murata; Azusa Ohta; Sho Yamasaki; Hiroaki Ikezaki; Kazuhiro Toyoda; Nobuyuki Shimono

doi:10.1016/j.jiac.2024.05.016

Corrigendum to “The humoral and cellular immune responses following booster vaccination with SARS-CoV-2 mRNA in people living with human immunodeficiency virus” [J. Infect. Chemother. 30 (2024) 417–422, (S1341321X23002866), (10.1016/j.jiac.2023.11.014)]

Yuji Matsumoto
, Masayuki Murata
, Azusa Ohta
, Sho Yamasaki
, Hiroaki Ikezaki
, Kazuhiro Toyoda
, Nobuyuki Shimono

Research output: Contribution to journal › Comment/debate › peer-review

Abstract

The authors regret the incorrect sentence currently read as: A total of 163 patients who received a primary series dose of mRNA SARS-CoV-2 vaccine (the BNT162b2 or mRNA-1273, NVX-CoV2373) were enrolled. The correct sentence should read as: A total of 163 patients who received a primary series dose of mRNA SARS-CoV-2 vaccine (the BNT162b2 or mRNA-1273) or a protein subunit vaccine (NVX-CoV2373) were enrolled. The authors would like to apologise for any inconvenience caused.

Original language	English
Pages (from-to)	1198
Number of pages	1
Journal	Journal of Infection and Chemotherapy
Volume	30
Issue number	11
DOIs	https://doi.org/10.1016/j.jiac.2024.05.016
Publication status	Published - Nov 2024

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

SDG 3 Good Health and Well-being

All Science Journal Classification (ASJC) codes

Microbiology (medical)
Pharmacology (medical)
Infectious Diseases

Access to Document

10.1016/j.jiac.2024.05.016

Fingerprint

Dive into the research topics of 'Corrigendum to “The humoral and cellular immune responses following booster vaccination with SARS-CoV-2 mRNA in people living with human immunodeficiency virus” [J. Infect. Chemother. 30 (2024) 417–422, (S1341321X23002866), (10.1016/j.jiac.2023.11.014)]'. Together they form a unique fingerprint.

Cite this

Matsumoto, Y., Murata, M., Ohta, A., Yamasaki, S., Ikezaki, H., Toyoda, K., & Shimono, N. (2024). Corrigendum to “The humoral and cellular immune responses following booster vaccination with SARS-CoV-2 mRNA in people living with human immunodeficiency virus” [J. Infect. Chemother. 30 (2024) 417–422, (S1341321X23002866), (10.1016/j.jiac.2023.11.014)]. Journal of Infection and Chemotherapy, 30(11), 1198. https://doi.org/10.1016/j.jiac.2024.05.016

Corrigendum to “The humoral and cellular immune responses following booster vaccination with SARS-CoV-2 mRNA in people living with human immunodeficiency virus” [J. Infect. Chemother. 30 (2024) 417–422, (S1341321X23002866), (10.1016/j.jiac.2023.11.014)]. / Matsumoto, Yuji; Murata, Masayuki ; Ohta, Azusa et al.
In: Journal of Infection and Chemotherapy, Vol. 30, No. 11, 11.2024, p. 1198.

Research output: Contribution to journal › Comment/debate › peer-review

Matsumoto, Y, Murata, M , Ohta, A , Yamasaki, S, Ikezaki, H, Toyoda, K & Shimono, N 2024, 'Corrigendum to “The humoral and cellular immune responses following booster vaccination with SARS-CoV-2 mRNA in people living with human immunodeficiency virus” [J. Infect. Chemother. 30 (2024) 417–422, (S1341321X23002866), (10.1016/j.jiac.2023.11.014)]', Journal of Infection and Chemotherapy, vol. 30, no. 11, pp. 1198. https://doi.org/10.1016/j.jiac.2024.05.016

Matsumoto Y, Murata M , Ohta A , Yamasaki S, Ikezaki H, Toyoda K et al. Corrigendum to “The humoral and cellular immune responses following booster vaccination with SARS-CoV-2 mRNA in people living with human immunodeficiency virus” [J. Infect. Chemother. 30 (2024) 417–422, (S1341321X23002866), (10.1016/j.jiac.2023.11.014)]. Journal of Infection and Chemotherapy. 2024 Nov;30(11):1198. doi: 10.1016/j.jiac.2024.05.016

Matsumoto, Yuji ; Murata, Masayuki ; Ohta, Azusa et al. / Corrigendum to “The humoral and cellular immune responses following booster vaccination with SARS-CoV-2 mRNA in people living with human immunodeficiency virus” [J. Infect. Chemother. 30 (2024) 417–422, (S1341321X23002866), (10.1016/j.jiac.2023.11.014)]. In: Journal of Infection and Chemotherapy. 2024 ; Vol. 30, No. 11. pp. 1198.

@article{2140d02c536a4551976f1331129f20b1,

title = "Corrigendum to {\textquotedblleft}The humoral and cellular immune responses following booster vaccination with SARS-CoV-2 mRNA in people living with human immunodeficiency virus{\textquotedblright} [J. Infect. Chemother. 30 (2024) 417{\textendash}422, (S1341321X23002866), (10.1016/j.jiac.2023.11.014)]",

abstract = "The authors regret the incorrect sentence currently read as: A total of 163 patients who received a primary series dose of mRNA SARS-CoV-2 vaccine (the BNT162b2 or mRNA-1273, NVX-CoV2373) were enrolled. The correct sentence should read as: A total of 163 patients who received a primary series dose of mRNA SARS-CoV-2 vaccine (the BNT162b2 or mRNA-1273) or a protein subunit vaccine (NVX-CoV2373) were enrolled. The authors would like to apologise for any inconvenience caused.",

keywords = "Types of vaccine",

author = "Yuji Matsumoto and Masayuki Murata and Azusa Ohta and Sho Yamasaki and Hiroaki Ikezaki and Kazuhiro Toyoda and Nobuyuki Shimono",

note = "Publisher Copyright: {\textcopyright} 2024 Japanese Society of Chemotherapy, Japanese Association for Infectious Diseases, and Japanese Society for Infection Prevention and Control",

year = "2024",

month = nov,

doi = "10.1016/j.jiac.2024.05.016",

language = "English",

volume = "30",

pages = "1198",

journal = "Journal of Infection and Chemotherapy",

issn = "1341-321X",

publisher = "Elsevier B.V.",

number = "11",

}

TY - JOUR

T1 - Corrigendum to “The humoral and cellular immune responses following booster vaccination with SARS-CoV-2 mRNA in people living with human immunodeficiency virus” [J. Infect. Chemother. 30 (2024) 417–422, (S1341321X23002866), (10.1016/j.jiac.2023.11.014)]

AU - Matsumoto, Yuji

AU - Murata, Masayuki

AU - Ohta, Azusa

AU - Yamasaki, Sho

AU - Ikezaki, Hiroaki

AU - Toyoda, Kazuhiro

AU - Shimono, Nobuyuki

PY - 2024/11

Y1 - 2024/11

N2 - The authors regret the incorrect sentence currently read as: A total of 163 patients who received a primary series dose of mRNA SARS-CoV-2 vaccine (the BNT162b2 or mRNA-1273, NVX-CoV2373) were enrolled. The correct sentence should read as: A total of 163 patients who received a primary series dose of mRNA SARS-CoV-2 vaccine (the BNT162b2 or mRNA-1273) or a protein subunit vaccine (NVX-CoV2373) were enrolled. The authors would like to apologise for any inconvenience caused.

AB - The authors regret the incorrect sentence currently read as: A total of 163 patients who received a primary series dose of mRNA SARS-CoV-2 vaccine (the BNT162b2 or mRNA-1273, NVX-CoV2373) were enrolled. The correct sentence should read as: A total of 163 patients who received a primary series dose of mRNA SARS-CoV-2 vaccine (the BNT162b2 or mRNA-1273) or a protein subunit vaccine (NVX-CoV2373) were enrolled. The authors would like to apologise for any inconvenience caused.

KW - Types of vaccine

UR - https://www.scopus.com/pages/publications/85196032679

UR - https://www.scopus.com/pages/publications/85196032679#tab=citedBy

U2 - 10.1016/j.jiac.2024.05.016

DO - 10.1016/j.jiac.2024.05.016

M3 - Comment/debate

C2 - 38825004

AN - SCOPUS:85196032679

SN - 1341-321X

VL - 30

SP - 1198

JO - Journal of Infection and Chemotherapy

JF - Journal of Infection and Chemotherapy

IS - 11

ER -

Corrigendum to “The humoral and cellular immune responses following booster vaccination with SARS-CoV-2 mRNA in people living with human immunodeficiency virus” [J. Infect. Chemother. 30 (2024) 417–422, (S1341321X23002866), (10.1016/j.jiac.2023.11.014)]

Abstract

UN SDGs

All Science Journal Classification (ASJC) codes

Access to Document

Other files and links

Fingerprint

Cite this